Erasca, Inc. SEC Filings

Erasca, Inc. (ERAS) reported a Form 144 notice showing proposed and recent sales of its common stock by an affiliated seller. The notice lists a proposed sale of 8,333 shares to be executed on 08/15/2025 on Nasdaq with an aggregate market value of $12,834.87. The shares were originally acquired by donation on 07/20/2021 from Erasca, Inc., with the donor amount recorded as 10,193,557 shares at donation. The filing also discloses three recent monthly sales by the Erasca Foundation of 8,333 shares each on 05/15/2025, 06/16/2025 and 07/15/2025, producing gross proceeds of $10,146.29, $12,090.87 and $12,094.60 respectively. The filing includes standard representations about absence of undisclosed material information and trading-plan attestations.

Logos Global Management LP, Logos Global Management GP LLC and William Arsani jointly reported beneficial ownership of 15,100,000 shares of Erasca, Inc. common stock, representing 5.3% of the outstanding shares based on 283,287,382 shares outstanding as of May 6, 2025. Each reporting person disclaims beneficial ownership except for pecuniary interest and reports shared voting and dispositive power over the 15,100,000 shares with no sole voting or dispositive power. The statement is filed on Schedule 13G, indicating a passive investment intent.

Erasca, Inc. (common stock, CUSIP 29479A108) is the subject of a joint Schedule 13G/A filed by multiple Frazier Life Sciences entities and individuals disclosing beneficial holdings of the issuer's common stock. Frazier Life Sciences Public Fund, L.P. directly holds 15,038,753 shares (5.3% of the class) based on 283,287,382 shares outstanding as of May 6, 2025. Additional Frazier vehicles report direct holdings of 2,405,634 shares (0.8%), 1,674,681 shares (0.6%), and 3,610,368 shares (1.3%) respectively.

The filing clarifies voting and dispositive power: the reporting persons state no sole voting or dispositive power over the disclosed shares and report shared voting and dispositive power for those amounts. The statement also corrects prior attributions, removing previously attributed ownership for certain committee members and clarifying the managerial structures that determine who shares investment authority.

Erasca, Inc. received Schedule 13G disclosures showing that Suvretta Capital Management, LLC and Aaron Cowen report beneficial ownership of 14,502,004 shares, equal to 5.1% of Erasca's common stock. Averill Master Fund, Ltd. reports 12,717,004 shares, or 4.5%. The filings show shared voting and dispositive power for those amounts and state the securities are held in the ordinary course of business and not to change or influence control. The document references Exhibits A and B and carries signatures dated 08/13/2025 with the report tied to the 06/30/2025 event.

Erasca, Inc. has filed a shelf registration providing flexibility to raise up to $500,000,000 of securities in one or more offerings, including common stock, preferred stock, debt securities, warrants and units. The filing also includes a sale-agreement prospectus for up to $200,000,000 of common stock that may be issued under an at-the-market Sale Agreement with Jefferies LLC; those shares are included in the $500,000,000 shelf amount. The prospectus states the companys common stock trades on Nasdaq under the symbol ERAS and reports a last sale price of $1.40 per share.

The document summarizes corporate governance and financing mechanics that matter to investors: authorized capital includes 800,000,000 common and 80,000,000 preferred shares; the board may issue undesignated preferred stock which could affect control and dilution; registration rights granted under a stockholders agreement terminate in August 2026. The prospectus also describes Erascas clinical-stage RAS/MAPK-focused pipeline, naming three clinical programs (naporafenib, ERAS-0015 and ERAS-4001) and a discovery program (ERAS-12), and directs investors to incorporated SEC reports for detailed financial and risk information.

Erasca reported total assets of $445.4 million and stockholders' equity of $372.3 million at June 30, 2025. The company held $386.7 million of combined cash, cash equivalents and marketable securities, and had an accumulated deficit of $832.5 million. The company states its cash and marketable securities are expected to fund operations for at least one year from issuance of these financial statements.

For the six months ended June 30, 2025 Erasca recorded a net loss of $64.8 million ($0.23 per share) and a net loss of $33.9 million for the quarter ended June 30, 2025 ($0.12 per share). Key program and corporate items disclosed include IND clearances in May 2025 for ERAS-0015 (AURORAS-1) and ERAS-4001 (BOREALIS-1), the in-license of naporafenib from Novartis, a strategic reprioritization to focus on naporafenib, ERAS-0015 and ERAS-4001, a $7.5 million IPR&D milestone expense related to the Joyo agreement in the period, and a subsequent Amended and Restated ATM agreement dated August 12, 2025 for up to $200 million.

Erasca, Inc. announced its financial results for the three months ended June 30, 2025 and furnished a press release containing the full results as Exhibit 99.1 to this Current Report. The filing notes the press release is being furnished rather than "filed," so it is not subject to Section 18 liability and is not incorporated by reference into other Securities Act or Exchange Act filings except by specific reference.

The Current Report identifies Exhibit 99.1 (press release) and a Cover Page Interactive Data File (104) as exhibits. No numerical financial data or consolidated financial statements are included in the text of this Form 8-K; readers are referred to the attached Exhibit 99.1 for the detailed results.

Erasca (Nasdaq: ERAS) filed a Form 8-K disclosing the 24 June 2025 annual meeting results. 241.8 million of 283.3 million entitled shares were represented (≈85%).

• Director elections: Jonathan Lim 196.99 M for / 2.19 M withheld; James Bristol 178.36 M for / 20.81 M withheld; Valerie Harding-Start 177.00 M for / 22.17 M withheld. All three Class I directors were elected for terms expiring in 2028.
• Auditor ratification: KPMG LLP received 240.25 M for, 1.27 M withheld, 0.31 M against; 0 broker non-votes.

No additional proposals were presented, and the filing notes no changes to governance, strategy, or capital structure.